BlackRock
AXSM icon

BlackRock’s Axsome Therapeutics AXSM Stock Holding History

BlackRock’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$661M Sell
3,912,844
-699
-0% -$121K 0.01% 915
2025
Q4 		$715M Buy
3,913,543
+122,614
+3% +$17.1M 0.01% 862
2025
Q3 		$460M Sell
3,790,929
-44,061
-1% -$4.96M 0.01% 1147
2025
Q2 		$400M Buy
3,834,990
+310,579
+9% +$32.9M 0.01% 1198
2025
Q1 		$411M Sell
3,524,411
-8,983
-0.3% -$1.02M 0.01% 1156
2024
Q4 		$299M Buy
3,533,394
+135,015
+4% +$12.4M 0.01% 1420
2024
Q3 		$305M Buy
3,398,379
+98,388
+3% +$8.59M 0.01% 1408
2024
Q2 		$266M Buy
3,299,991
+104,501
+3% +$7.74M 0.01% 1424
2024
Q1 		$255M Sell
3,195,490
-44,256
-1% -$3.71M 0.01% 1483
2023
Q4 		$258M Buy
3,239,746
+305,256
+10% +$20.4M 0.01% 1481
2023
Q3 		$205M Buy
2,934,490
+210,947
+8% +$15.8M 0.01% 1527
2023
Q2 		$196M Buy
2,723,543
+255,319
+10% +$18.8M 0.01% 1596
2023
Q1 		$152M Sell
2,468,224
-34,753
-1% -$2.28M ﹤0.01% 1747
2022
Q4 		$193M Buy
2,502,977
+310,722
+14% +$18.6M 0.01% 1555
2022
Q3 		$97.8M Sell
2,192,255
-36,822
-2% -$1.84M ﹤0.01% 1979
2022
Q2 		$85.4M Buy
2,229,077
+136,820
+7% +$4.33M ﹤0.01% 2124
2022
Q1 		$86.6M Sell
2,092,257
-17,365
-0.8% -$538K ﹤0.01% 2222
2021
Q4 		$79.7M Buy
2,109,622
+41,559
+2% +$1.53M ﹤0.01% 2362
2021
Q3 		$68.2M Sell
2,068,063
-52,691
-2% -$2.05M ﹤0.01% 2455
2021
Q2 		$143M Sell
2,120,754
-199,039
-9% -$11.9M ﹤0.01% 2019
2021
Q1 		$131M Buy
2,319,793
+40,027
+2% +$2.82M ﹤0.01% 2018
2020
Q4 		$186M Buy
2,279,766
+16,007
+0.7% +$1.2M 0.01% 1680
2020
Q3 		$161M Sell
2,263,759
-129,708
-5% -$10.1M 0.01% 1564
2020
Q2 		$197M Buy
2,393,467
+138,817
+6% +$10.7M 0.01% 1378
2020
Q1 		$133M Buy
2,254,650
+94,404
+4% +$7.69M 0.01% 1456
2019
Q4 		$223M Buy
2,160,246
+349,369
+19% +$14.1M 0.01% 1402
2019
Q3 		$36.7M Buy
1,810,877
+120,355
+7% +$3.09M ﹤0.01% 2473
2019
Q2 		$43.5M Buy
1,690,522
+1,224,935
+263% +$24.6M ﹤0.01% 2400
2019
Q1 		$6.63M Buy
465,587
+401,538
+627% +$3.73M ﹤0.01% 3309
2018
Q4 		$181K Buy
64,049
+8,137
+15% +$26.8K ﹤0.01% 4251
2018
Q3 		$193K Buy
55,912
+2,195
+4% +$6.51K ﹤0.01% 4322
2018
Q2 		$172K Buy
53,717
+7,058
+15% +$21.9K ﹤0.01% 4341
2018
Q1 		$115K Sell
46,659
-644
-1% -$1.93K ﹤0.01% 4309
2017
Q4 		$265K Buy
47,303
+2,040
+5% +$10.3K ﹤0.01% 4160
2017
Q3 		$251K Sell
45,263
-1,358
-3% -$7.29K ﹤0.01% 4184
2017
Q2 		$257K Sell
46,621
-444,884
-91% -$1.86M ﹤0.01% 4190
2017
Q1 		$1.92M Buy
491,505
+491,086
+117,204% +$2.35M ﹤0.01% 3663
2016
Q4 		$3K Hold
419
– – ﹤0.01% 3573
2016
Q3 		$3K Hold
419
– – ﹤0.01% 3545
2016
Q2 		$3K Buy
+419
New +$3.86K ﹤0.01% 3568

Other funds holding AXSM

VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BlackRock's AXSM Position: Q1 2026 in Review

BlackRock reduced its Axsome Therapeutics (AXSM) stake by 0.02% in Q1 2026, selling an estimated $121K and leaving 3,912,844 shares worth $661M. The position accounts for 0.01% of the portfolio, ranked #915.

BlackRock first reported a position in AXSM in Q2 2016 and has held it in 40 quarters since. The position peaked at $715M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • BlackRock held 3,912,844 shares of Axsome Therapeutics worth $661M as of Q1 2026.
  • BlackRock sold 699 Axsome Therapeutics shares in Q1 2026, an estimated $121K.
  • Axsome Therapeutics made up 0.01% of BlackRock's portfolio in Q1 2026, its #915 holding.
  • BlackRock first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • BlackRock's Axsome Therapeutics position peaked at $715M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.